ElMaestro
★★★

Denmark,
2018-08-15 11:02

Posting: # 19169
Views: 872

## Spelling out FDA's pop BE model [General Sta­tis­tics]

Dear all,

I am trying to spell out the underlying model of FDA's pop BE analysis used for in vitro comparison of signle actuator content and more. A link is here.

The players are:

The formulations (F, two levels)
The stages (S, three levels in FDA's example, but may be anything from one upwards)
The cans ("Cans in batch", C, at least ten levels)
The batches ("batch within formulation", B, at least three levels)

I was initially thinking
Y=F+S+C+B+ek where ek is N(0, MSWk), and where Y is the in vitro metric we are sampling, like SAC, and where we's consider C, possibly B and S random (?).

But since MSWk comes from sampling across stages, I am inclined to work without S, so
a. Y=F+C+B+ek,
where C and possibly B are random. When there is only a single sampled stage I guess this would then be
b. Y=F+B+ek where ek is then N(0, MSBk)

What's your opinion on a. and b.?
How would you formulate the models yourself?

``` if (3) 4 x=c("Foo", "Bar") b=data.frame(x) typeof(b[,1]) ##aha, integer? b[,1]+1 ##then let me add 1```

Best regards,
ElMaestro

“(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures.” New York Times (ed.), June 9, 2018.
nobody
nothing

2018-08-17 09:18

@ ElMaestro
Posting: # 19170
Views: 664

## Spelling out FDA's pop BE model

...maybe a post to the NONMEM users would be an option?

nmusers@globomaxnm.com

Kindest regards, nobody
Bioequivalence and Bioavailability Forum |  Admin contact
19,405 posts in 4,122 threads, 1,323 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time (Europe/Vienna): 04:11 CEST

[Those] who have an excessive faith in their theories or in their
ideas are not only poorly disposed to make discoveries, but they
also make very poor observations.    Claude Bernard

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
Ing. Helmut Schütz